Authors
Joshua J Solomon, Sonye K Danoff, Felix A Woodhead, Shelley Hurwitz, Rie Maurer, Ian Glaspole, Paul F Dellaripa, Bibek Gooptu, Robert Vassallo, P Gerard Cox, Kevin R Flaherty, Huzaifa I Adamali, Michael A Gibbons, Lauren Troy, Ian A Forrest, Joseph A Lasky, Lisa G Spencer, Jeffrey Golden, Mary Beth Scholand, Nazia Chaudhuri, Mark A Perrella, David A Lynch, Daniel C Chambers, Martin Kolb, Cathie Spino, Ganesh Raghu, Hilary J Goldberg, Ivan O Rosas, Shana Haynes-Harp, Fernando Poli, Coimbatore Sree Vidya, Rebecca R Baron, Timothy Clouser, Tracy Doyle, Anthony Maeda, Kristin B Highland, Jemima F Albayda, Sarah E Collins, Karthik S Suresh, John M Davis, Andrew H Limper, Isabel Amigues, Kristina Eliopoulos, Jeffery J Swigris, Stephen Humphries, John C Huntwork, Chris Glynn, Steve R Duncan, Maria I Danila, Marilyn K Glassberg, Elana M Oberstein, Elizabeth A Belloli, Linda Briggs, Vivek Nagaraja, Linda Cholewa, Donna DiFranco, Edward Green, Christie Liffick, Tanvi Naik, Genevieve Montas, Dorota Lebiedz-Odrobina, Reba Bissell, Mark Wener, Lisa H Lancaster, Leslie J Crawford, Karmela Chan, Robert J Kaner, Alicia Morris, Xiaoping Wu, Nader A Khalidi, Christopher J Ryerson, Alyson W Wong, Charlene D Fell, Sharon A LeClercq, Mark Hyman, Shane Shapera, Shikha Mittoo, Shireen Shaffu, Karl Gaffney, Andrew M Wilson, Shaney Barratt, Harsha Gunawardena, Rachel K Hoyles, Joel David, Namrata Kewalramani, Toby M Maher, Philip L Molyneaux, Maria A Kokosi, Matthew J Cates, Mandizha Mandizha, Abdul Ashish, Gladstone Chelliah, Helen Parfrey, Muhunthan Thillai, Josephine Vila, Sophie V Fletcher, Paul Beirne, Clair Favager, Jo Brown, Julie K Dawson, Pilar Rivera Ortega, Sahena Haque, Pippa Watson, Jun K Khoo, Karen Symons, Peter Youssef, John A Mackintosh
Publication date
2023/1/1
Journal
The Lancet Respiratory Medicine
Volume
11
Issue
1
Pages
87-96
Publisher
Elsevier
Description
Background
Interstitial lung disease is a known complication of rheumatoid arthritis, with a lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety, tolerability, and efficacy of pirfenidone for the treatment of patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Methods
TRAIL1 was a randomised, double-blind, placebo-controlled, phase 2 trial done in 34 academic centres specialising in interstitial lung disease in four countries (the UK, the USA, Australia, and Canada). Adults aged 18–85 years were eligible for inclusion if they met the 2010 American College of Rheumatology and European Alliance of Associations for Rheumatology criteria for rheumatoid arthritis and had interstitial lung disease on a high-resolution CT scan imaging and, when available, lung biopsy. Exclusion criteria include smoking, clinical history of other known causes of interstitial …
Total citations
Scholar articles
JJ Solomon, SK Danoff, FA Woodhead, S Hurwitz… - The Lancet Respiratory Medicine, 2023